This inventor holds 2 USPTO granted patents. Top assignees: Nanjing Sanhome Pharmaceutical Co., Ltd., Shanghai Dimaihe Biotechnology Co., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Innovations in Hair Loss Treatment by Liang Jin
Introduction
Liang Jin is an innovative inventor based in Nanjing, China. He has made significant contributions to the field of biotechnology, particularly in the treatment of androgenic alopecia. His work focuses on the use of flibanserin, a drug that has shown promise in reversing hair loss.
Latest Patents
Liang Jin holds a patent for the "Use of flibanserin in preparation of drug for treating androgenic alopecia." This invention reveals that flibanserin can inhibit the proliferation of Lncap cells at low concentrations, demonstrating pharmacodynamic activity at the cellular level. Furthermore, animal experiments indicate that flibanserin can reverse androgen-mediated damage associated with androgenic alopecia, effectively treating the condition and restoring hair growth. This patent highlights the potential of flibanserin as a therapeutic agent in hair loss treatments.
Career Highlights
Liang Jin is currently associated with Shanghai Dimaihe Biotechnology Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its innovative approach to addressing hair loss, a condition that affects many individuals worldwide.
Collaborations
Liang Jin collaborates with Yingjie Sun, contributing to the advancement of their shared research goals. Their partnership exemplifies the importance of teamwork in the field of biotechnology.
Conclusion
Liang Jin's innovative work in the use of flibanserin for treating androgenic alopecia represents a significant advancement in hair loss therapies. His contributions to biotechnology continue to pave the way for new treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile